Publicación:
COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Vista sencilla de ítem
dc.creatorFürstenau, Moritz
dc.creatorLangerbeins, Petra
dc.creatorDe Silva, Nisha
dc.creatorFink, Anna Maria
dc.creatorRobrecht, Sandra
dc.creatorvon Tresckow, Julia
dc.creatorSimon, Florian
dc.creatorHohloch, Karin
dc.creatorDroogendijk, Jolanda
dc.creatorvan der Klift, Marjolein
dc.creatorvan der Spek, Ellen
dc.creatorIllmer, Thomas
dc.creatorSchöttker, Björn
dc.creatorFischer, Kirsten
dc.creatorWendtner, Clemens M.
dc.creatorTausch, Eugen
dc.creatorStilgenbauer, Stephan
dc.creatorNiemann, Carsten U.
dc.creatorGregor, Michael
dc.creatorKater, Arnon P.
dc.creatorHallek, Michael
dc.creatorEichhorst, Barbara
dc.date.accessioned2020-09-08T13:52:55Z
dc.date.available2020-09-08T13:52:55Z
dc.date.created2020-06-29
dc.description.abstractenglishWith more than 5 million proven infections and more than 300,000 associated deaths worldwide [1], the SARS-CoV-2 pandemic poses unprecedented challenges to health-care professionals and especially those treating and caring for patients with malignant hematological diseases. These patients often have multiple different risk factors for severe infections [2]. Chronic lymphocytic leukemia (CLL) is the most common form of leukemia and infections are a known contributor to morbidity and mortality due to a disease-inherent immunodeficiency [3, 4]. Considering this multifactorial immune defect, it appears conceivable that patients with CLL are more susceptible to infections with SARS-CoV-2 and more likely to develop severe courses of the associated respiratory disease COVID-19, especially when under additional immunosuppression by chemoimmunotherapy (CIT). Few case reports on COVID-19 in CLL patients from countries with suspected different prevalence rates of COVID-19 have been published so far. The publications report a patient after first-line treatment with single-agent chlorambucil, a case series with four treatment-naive CLL patients, a case series of eight patients on Bruton tyrosine kinase (BTK) inhibitors and most recently a heterogeneously treated population of four patients from the Hospital Clinic of Barcelona [5,6,7,8]. While it has been hypothesized that the BTK inhibitor ibrutinib might have protective effects against COVID-19 by attenuating hyperinflammatory responses, there is currently no data on COVID-19 in patients receiving venetoclax-based treatments [7, 9]. A recent study has suggested a reduction of CLL-inherent immunosuppression after successful treatment with venetoclax-based regimens [10]. In light of these data we sought to determine the incidence, severity, and possible risk factors of COVID-19 cases in a well-defined cohort of patients with CLL receiving venetoclax-based combination treatments as first-line therapy in a prospective clinical trial.spa
dc.format.extent5 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41375-020-0941-7spa
dc.identifier.issn1476-5551spa
dc.identifier.otherhttps://www.nature.com/articles/s41375-020-0941-7spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/12895
dc.language.isoengspa
dc.publisherChronic lymphocytic leukemiaspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.localAcceso restringidospa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectvenetoclaxspa
dc.subjectleukemiaspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleCOVID-19 among fit patients with CLL treated with venetoclax-based combinationsspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa
dspace.entity.typePublication

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.pdf
Tamaño:
446.4 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento con derechos reservados
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS